BOSTON (

TheStreet

) --Welcome to June's Biotech Stock Mailbag Live Chat. The floor is yours.

I'm here for the next 90 minutes or so to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing in the box below.

The

American Society of Clinical Oncology

(ASCO) annual meeting that just ended raised some controversies and issues surrounding

Exelixis

(EXEL) - Get Report

,

YM BioSciences

( YMI) and

Neoprobe

(NEOP)

, so let's discuss.

If you're interested in FDA drug approval decisions, we can hash out the looming catalysts for

Fibrocell Sciences

(FCSC.OB)

,

Transcept Pharmaceuticals

(TSPT)

,

NuPathe

(PATH)

or

Seattle Genetics

(SGEN) - Get Report

.

What's the real story behind

Titan Pharmaceuticals'

(TTNP.OB)

surprise announcement this morning disclosing an FDA meeting to change the statistical plan for the ongoing phase III study of Probuphine?

Ask me questions about the large-cap biotech stocks:

Biogen Idec

(BIIB) - Get Report

,

Celgene

(CELG) - Get Report

,

Amgen

(AMGN) - Get Report

and

Gilead Sciences

(GILD) - Get Report

.

Has anyone figured out why

Spectrum Pharmaceuticals

(SPPI) - Get Report

wants to buy back its stock? Why is

Allos Therapeutics

( ALTH) trading below $2 a share? Will

Cell Therapeutics

(CTIC) - Get Report

ever get a new drug approved? Is there any reason to be optimistic about stem cell stocks like

Aastrom Biosciences

(ASTM)

,

Cytori Therapeutics

(CYTX)

or

Geron

(GERN) - Get Report

?

Let's talk about these stocks today, or any other biotech investing subjects that pique your interest. Please join me live.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.